The available trials have not established GLP-1 drugs as a way to quit smoking. As in GLP-1 studies for opioid use disorder, researchers measure cravings and actual substance use separately. An improvement in craving alone does not show that more people quit.[1][2]
What the quit-smoking trials found
A review that searched for studies through November 2025 pooled 337 analyzed participants from two randomized trials. The odds ratio for quitting was 1.36 (95% CI 0.55–3.35). The interval includes the possibility of lower or higher odds with treatment, and the authors rated the evidence very low certainty.[1]
In the smaller pilot, 46.3% of people receiving exenatide were abstinent at six weeks compared with 26.8% receiving placebo. Both groups used nicotine patches and counseling. The estimate was uncertain (risk ratio 1.70, 95% credible interval 0.96–3.27). In the larger trial, abstinence at 12 weeks was 63% with dulaglutide and 65% with placebo. Both groups received varenicline and counseling.[3][4]
What the semaglutide trial added
A 2026 laboratory study randomized 24 adults who smoked daily, and 21 completed the primary outcome assessment. Semaglutide did not significantly improve participants’ ability to delay smoking in the laboratory or reduce cigarettes smoked per day in weekly reports. Participants assigned semaglutide did report lower nicotine craving on some measures. The trial was designed to measure smoking behavior and craving during treatment rather than sustained abstinence.[2]
Weight is a separate outcome
The earlier review found lower post-cessation weight with GLP-1 drugs than with controls. That comparison addresses weight change during a quit attempt. It cannot show whether the lower weight helped people stay smoke-free.[1]